Latest Research

G Schepici et al, 2020. Caffeine: An overview of its beneficial effects in experimental models and clinical trials of Parkinson's disease, International Journal of Molecular Science, Volume 21 (13).

C H Tong et al, 2020. The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis, Nutrients, Volume 12 (6)

J W Kim et al, 2019. Coffee intake and decreased amyloid pathology in human brain, Translational Psychiatry, Volume 9 (1).

C Boulos et al, 2019. Nutritional Risk Factors, Microbiota and Parkinson's Disease: What Is the Current Evidence, Nutrients, Volume 11 (8).

M A Kromhout et al, 2019. Caffeine and neuropsychiatric symptoms in patients with dementia: a systematic review, Experimental Gerontology, published online.

S C Larsson and N Orsini, 2018. Coffee Consumption and Risk of Dementia and Alzheimer's Disease: A Dose-response Meta-Analysis of Prospective Studies, Nutrients, Volume 10 (10).

A Hussain et al, 2018. Caffeine: a potential protective agent against cognitive decline in Alzheimer’s disease, Critical Review in Eukaryiotic Gene Expression, Volume 28 (1).

B H Cho et al, 2018. Association of Coffee Drinking and Non-motor Symptoms in Drug Naive, Early Stage Parkinson's Disease, Parkinsonism and Related Disorders, published online.

I Y Kim et al, 2018. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Movement Disorders, published online.

M Fujimaki et al, 2018. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease, Neurology, published online.

This information is intended for Healthcare professional audiences.
Please consider the environment before printing.